Nuveen LLC Takes Position in Sarepta Therapeutics, Inc. $SRPT

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Nuveen LLC bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 352,740 shares of the biotechnology company's stock, valued at approximately $22,512,000. Nuveen LLC owned 0.36% of Sarepta Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in SRPT. Entropy Technologies LP acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth $1,436,000. Pandora Wealth Inc. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth $45,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Sarepta Therapeutics by 66.2% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 244,769 shares of the biotechnology company's stock worth $15,621,000 after buying an additional 97,533 shares in the last quarter. CenterBook Partners LP acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth $281,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Sarepta Therapeutics by 3.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 646,291 shares of the biotechnology company's stock worth $41,246,000 after buying an additional 22,542 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Trading Down 2.5%

Shares of SRPT stock traded down $0.52 during mid-day trading on Thursday, hitting $20.06. The company's stock had a trading volume of 16,664,559 shares, compared to its average volume of 6,203,780. The company's fifty day simple moving average is $18.65 and its 200-day simple moving average is $52.02. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $144.22. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The company has a market cap of $1.96 billion, a PE ratio of -23.06 and a beta of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. During the same period last year, the company posted $0.07 EPS. The business's quarterly revenue was up 68.4% on a year-over-year basis. As a group, equities research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SRPT has been the subject of a number of research analyst reports. Needham & Company LLC reissued an "underperform" rating on shares of Sarepta Therapeutics in a report on Monday, July 28th. TD Cowen cut Sarepta Therapeutics from a "buy" rating to a "hold" rating and set a $24.00 price target for the company. in a report on Wednesday, June 18th. Wells Fargo & Company boosted their price target on Sarepta Therapeutics from $48.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, August 7th. Mizuho restated a "neutral" rating and set a $14.00 price objective (down previously from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Finally, Leerink Partners restated a "market perform" rating on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Eight equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $43.50.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.